PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Amendment

21 May 2014 17:35

RNS Number : 7502H
GoldmanSachs International
21 May 2014
 

Amendment - due to the amendment of Equity and Derivative transactions, the disclosure made on 19 May for dealings on 15 May has been updated. Sections 2(a) and 2(b) have been updated.

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN SACHS INTERNATIONAL

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ASTRAZENECA PLC

(d) Date dealing undertaken:

15 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES - disclosed previously for PFIZER INC

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

USD 0.25 ordinary

Purchases

478,7205,521

47.2650 GBP521.0000 SEK

46.3450 GBP516.8859 SEK

USD 0.25 ordinary

Sales

541,5444,234

47.2650 GBP518.0000 SEK

46.4250 GBP513.5000 SEK

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

USD 0.25 ordinary

CFD

Reducing a long position

7,500

46.2204 GBP

USD 0.25 ordinary

CFD

Reducing a long position

5,329

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

11,622

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

30,000

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

26,049

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a long position

2,000

46.5272 GBP

USD 0.25 ordinary

CFD

Reducing a short position

245

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a short position

184

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a short position

529

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a short position

748

46.6998 GBP

USD 0.25 ordinary

CFD

Reducing a long position

871

46.7683 GBP

USD 0.25 ordinary

CFD

Reducing a long position

2,929

46.7683 GBP

USD 0.25 ordinary

CFD

Reducing a long position

50,000

46.8725 GBP

USD 0.25 ordinary

CFD

Opening a short position

11,000

46.9343 GBP

USD 0.25 ordinary

CFD

Opening a short position

14

46.9499 GBP

USD 0.25 ordinary

CFD

Opening a short position

121

46.9499 GBP

USD 0.25 ordinary

CFD

Opening a long position

63,022

47.0760 GBP

USD 0.25 ordinary

CFD

Reducing a long position

1,548

47.2650 GBP

USD 0.25 ordinary

CFD

Opening a long position

2,000

47.2650 GBP

USD 0.25 ordinary

CFD

Reducing a short position

7,500

77.9456 USD

USD 0.25 ordinary

CFD

Reducing a short position

75,000

78.1656 USD

USD 0.25 ordinary

CFD

Reducing a short position

50,000

78.7457 USD

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

21 May 2014

Contact name:

Aadithya Rao and Yiannis Bardis

Telephone number:

+44(20) 7051 9046 / +44(20) 7774 7107

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERPGUAWAUPCGQG
Date   Source Headline
25th Jan 20217:00 amRNSCalquence met primary endpoint against ibrutinib
20th Jan 20217:00 amRNSEnhertu approved in the EU for breast cancer
18th Jan 20217:00 amRNSEnhertu approved in the US for gastric cancer
15th Jan 20217:00 amRNSImfinzi new dosing approved in EU
6th Jan 20217:00 amRNSFarxiga granted US Priority Review for CKD
4th Jan 20213:00 pmRNSTotal Voting Rights
4th Jan 20217:00 amRNSAtacand divestment in over 70 countries completed
30th Dec 20207:00 amRNSAstraZeneca’s COVID-19 vaccine authorised in UK
29th Dec 20207:00 amRNSLynparza approved in Japan for three cancers
21st Dec 20207:05 amRNSTagrisso approved in the US for early lung cancer
21st Dec 20207:00 amRNSUpdate on US regulatory review of roxadustat
17th Dec 20204:00 pmRNSDirector/PDMR Shareholding
16th Dec 20206:15 pmRNSDirector/PDMR Shareholding
15th Dec 20207:00 amRNSImfinzi new dose receives positive EU CHMP opinion
14th Dec 20207:05 amRNSTrastuzumab deruxtecan positive CHMP
14th Dec 20207:00 amRNSTrixeo Aerosphere approved in the EU for COPD
14th Dec 20207:00 amRNSAstraZeneca to acquire Alexion Pharmaceuticals Inc
1st Dec 20203:00 pmRNSBlock listing Interim Review
1st Dec 20203:00 pmRNSTotal Voting Rights
1st Dec 20207:00 amRNSCrestor to be divested to Grünenthal in Europe
30th Nov 20207:00 amRNSForxiga approved in Japan for heart failure
23rd Nov 20207:00 amRNSAZD1222 vaccine effective against COVID-19
20th Nov 20207:00 amRNSImfinzi new dosing approved in the US
10th Nov 20207:00 amRNSTezepelumab Phase III trial met primary endpoint
9th Nov 20207:00 amRNSCalquence approved in the EU for CLL
6th Nov 20207:00 amRNSBrilinta approved in the US in stroke
5th Nov 20207:15 amRNSLynparza approved in the EU for wider ovarian use
5th Nov 20207:10 amRNSLynparza approved in the EU for prostate cancer
5th Nov 20207:05 amRNSForxiga approved in the EU for heart failure
5th Nov 20207:00 amRNSAZN: Year-to-date and Q3 2020 results
2nd Nov 20203:00 pmRNSTotal Voting Rights
30th Oct 20207:00 amRNSAtacand to be divested in more than 70 countries
29th Oct 20207:00 amRNSDirectorate Change
28th Oct 20207:03 amRNSEnhertu US Priority Review in gastric cancer
28th Oct 20207:00 amRNSForxiga CV outcomes benefit approved in China
20th Oct 20207:00 amRNSTagrisso adjuvant lung cancer US Priority Review
19th Oct 20207:00 amRNSForxiga HF receives positive CHMP opinion
19th Oct 20207:00 amRNSTrixeo Aerosphere receives positive CHMP opinion
12th Oct 20207:00 amRNSCOVID-19 antibodies advance and get US funding
2nd Oct 202011:19 amRNSHolding(s) in Company
2nd Oct 20207:00 amRNSFarxiga granted US BTD in chronic kidney disease
1st Oct 20203:00 pmRNSTotal Voting Rights
25th Sep 20207:00 amRNSDirectorate Change
21st Sep 20207:05 amRNSLynparza EU recommendation in prostate cancer
21st Sep 20207:00 amRNSLynparza EU recommendation in ovarian cancer
21st Sep 20207:00 amRNSTagrisso reduced early lung cancer brain recurrenc
10th Sep 20207:01 amRNSAstraZeneca to list all US securities on Nasdaq
10th Sep 20207:00 amRNSFasenra PhIII OSTRO trial met co-primary endpoints
1st Sep 20203:00 pmRNSTotal Voting Rights
1st Sep 20207:00 amRNSImfinzi approved in EU for small cell lung cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.